Chemed Earnings Reports

Chemed Corporation reported Q4 2024 revenue of $640.0 million, an increase of 9.2% year-over-year. Net income attributable to common stock was $90.3 million, with EPS of $6.02 and adjusted EPS of $6.83. VITAS segment revenue grew 17.4%, while Roto-Rooter saw a slight revenue decline. Free cash flow remained strong, and the company repurchased shares worth $212.8 million.

Chemed Corporation reported a 7.4% increase in revenue to $606.2 million for Q3 2024. GAAP diluted EPS increased by 1.4% to $5.00, and adjusted diluted EPS rose by 6.0% to $5.64. The VITAS segment saw a 17.3% increase in net patient revenue, while Roto-Rooter's revenue decreased by 6.9%.

Chemed Corporation reported a 7.6% increase in revenue to $595.9 million and a 34.1% increase in adjusted diluted EPS to $5.47 for the second quarter of 2024. The VITAS segment saw a significant revenue increase of 16.7%, while Roto-Rooter experienced a 5.0% revenue decrease.

Chemed Corporation reported a 5.2% increase in revenue to $589.2 million and a GAAP diluted EPS of $4.24, up 18.4%. Adjusted diluted EPS increased by 21.5% to $5.20. VITAS Healthcare saw a 14.0% increase in net patient revenue, while Roto-Rooter experienced a 5.8% decrease in revenue.

Chemed Corporation reported a 7.2% increase in revenue to $585.9 million and a 42.9% increase in GAAP EPS to $5.90 for the fourth quarter of 2023. Adjusted EPS increased by 35.0% to $6.60. VITAS Healthcare saw a 13.6% increase in net patient revenue, while Roto-Rooter's revenue decreased slightly by 1.1%.

Chemed Corporation reported a 1.0% increase in revenue to $547 million for Q4 2022. GAAP diluted EPS was $4.13, and adjusted diluted EPS increased by 2.7% to $5.39. The VITAS segment experienced a revenue decline, while Roto-Rooter showed revenue growth.

Chemed Corporation reported third-quarter 2022 results, with revenue declining by 2.3% to $526 million. GAAP diluted EPS was $3.78, and adjusted diluted EPS decreased by 6.3% to $4.74. The company increased its 2022 earnings guidance.

Chemed Corporation reported a slight decline in revenue but an increase in GAAP diluted earnings per share. The VITAS segment experienced revenue and ADC declines, while Roto-Rooter saw revenue growth.

Chemed Corporation reported a slight increase in revenue for Q1 2022, with overall revenue rising by 0.6% to $531 million. While Roto-Rooter saw a revenue increase, VITAS experienced a decline. GAAP EPS increased by 5.2% to $4.22, and adjusted EPS increased by 7.9% to $4.79.

Chemed Corporation reported a 1.4% increase in revenue to $541 million. GAAP EPS was $4.81 and adjusted EPS increased by 2.3% to $5.25. The VITAS segment experienced revenue and ADC declines while Roto-Rooter saw revenue and net income growth.

Chemed Corporation reported a 2.0% increase in revenue to $539 million. GAAP diluted EPS increased by 9.9% to $4.55, and adjusted diluted EPS increased by 4.1% to $5.06. The VITAS segment experienced a revenue decline, while Roto-Rooter demonstrated strong revenue growth.

Chemed Corporation reported a 6.0% increase in revenue to $532 million for Q2 2021. GAAP EPS decreased by 29.9% to $3.51, while adjusted EPS increased by 4.3% to $4.60. The VITAS segment experienced declines in net patient revenue and ADC, while the Roto-Rooter segment saw significant revenue growth.

Chemed Corporation reported a 2.2% increase in revenue to $527 million for Q1 2021. GAAP Diluted EPS increased by 18.6% to $4.01, and Adjusted Diluted EPS rose by 20.7% to $4.44. The VITAS segment experienced a revenue decline, while Roto-Rooter saw significant revenue growth.

Chemed Corporation reported a 2.1% increase in revenue to $533 million. GAAP diluted EPS increased by 75.8% to $6.96, and adjusted diluted EPS increased by 21.6% to $5.13. VITAS segment revenue declined by 2.3%, while Roto-Rooter's revenue increased by 10.2%.

Chemed Corporation reported a 9.9% increase in revenue, reaching $528 million. GAAP diluted EPS increased by 16.3% to $4.14, and adjusted diluted EPS increased by 40.5% to $4.86. The VITAS segment saw a 4.8% increase in net patient revenue, while Roto-Rooter experienced a 20.4% increase in revenue.

Chemed Corporation reported a 6.0% increase in revenue to $502 million. GAAP diluted EPS increased by 62.7% to $5.01, and adjusted diluted EPS increased by 31.3% to $4.41.

Chemed Corporation reported an 11.6% increase in revenue to $516 million for the first quarter of 2020. GAAP diluted EPS increased by 25.2% to $3.38, and adjusted diluted EPS increased by 26.0% to $3.68.

Chemed Corporation reported a 14.2% increase in revenue to $522 million for Q4 2019. GAAP diluted EPS increased by 21.5% to $3.96, and adjusted diluted EPS increased by 26.0% to $4.22.